Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04052997
Title Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors ADC Therapeutics S.A.
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL


No variant requirements are available.